What is the usage and dosage of Quizartinib? What is the correct usage and dosage?

Quizartinib is an oral targeted drug mainly used to treat specific types of leukemia, especially acute myeloid leukemia (AML) with FLT3 mutations. It inhibits the activity of FLT3 receptor tyrosine kinase, thereby interfering with the proliferation of cancer cells and playing an anti-tumor effect. The correct usage and dosage need to be adjusted according to the patient's specific condition, weight and doctor's instructions.

1. Recommended dose: The standard recommended dose of quizartinib is usually 35.4 mg taken orally once daily. Usually at the beginning of treatment, patients should take the medication continuously. To ensure effectiveness, medications should be taken within a fixed time frame to avoid missed doses. If you miss a dose, you should take it as soon as possible, but if it is near the time for the next dose, skip the missed dose and continue taking it as originally planned.

2. Treatment cycle: The treatment cycle of Quizartinib is usually 28 days. Patients may need to adjust the treatment cycle based on clinical response. After each cycle, the doctor will evaluate the patient's condition and side effects and decide whether to continue treatment. In some cases, your doctor may adjust the dose based on the degree of therapeutic effect and side effects.

3. Drug Precautions: While taking Quizartinib, patients should undergo regular blood routine examinations to monitor white blood cells, platelets and other components in the blood. Since quizartinib may cause side effects such as bone marrow suppression and liver function damage, doctors will regularly monitor liver and kidney function and other related indicators. If serious side effects or adverse reactions occur, the dose may need to be adjusted or the medication may need to be temporarily discontinued.

4. Special groups: For patients with liver and renal impairment, the dosage of quizartinib may need to be adjusted. In the case of liver insufficiency, patients should use this drug under the guidance of a doctor and pay close attention to liver function indicators. Additionally, the use of quizartinib should be avoided in pregnant and nursing women unless the potential benefits of use are clearly stated to outweigh the risks.

In short, quizartinib, as a targeted drug targeting FLT3 mutations, plays an important role in the treatment of acute myeloid leukemia. Patients should strictly follow the doctor's instructions when using it and conduct regular health check-ups.

Reference materials:https://go.drugbank.com/drugs/DB12874